| 03/28/2025 16:00 |
Notice of Transition to Company with an Audit & Supervisory Committee |
| 03/26/2025 11:30 |
Notice Regarding Refinancing of Existing Borrowings Through a Syndicated Loan |
| 02/28/2025 15:30 |
Notice of Capital Reorganization within Sumitomo Pharma Group |
| 01/31/2025 15:30 |
Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2025 [IFRS] |
| 01/31/2025 15:30 |
Conference on Q3 FY2024 (April 1, 2024 to December 31, 2024) Financial Results |
| 01/31/2025 15:30 |
Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2025 |
| 01/31/2025 15:30 |
Sumitomo Pharma Announces Revisions to Its Financial Forecasts |
| 01/31/2025 15:30 |
Notice Concerning Finance Income |
| 01/20/2025 15:30 |
Sumitomo Pharma Announces Agreement on Co-Promotion Collaboration Partner for Marketing of PPLAT XEPLION and XEPLION TRI in Japan |
| 10/30/2024 13:30 |
Sumitomo Pharma Announces the Results of Its Early Retirement Program Offer to Employees in Japan for Business Structural Reform |
| 10/30/2024 13:30 |
Notice Concerning Finance Costs |
| 10/30/2024 13:30 |
Conference on Q2 FY2024 (April 1, 2024 to September 30, 2024) Financial Results |
| 10/30/2024 13:30 |
Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 2025 |
| 10/30/2024 13:30 |
Summary of Consolidated Financial Results for the Second Quarter (First Half) of the Year Ending March 31, 2025 [IFRS] |
| 07/31/2024 15:30 |
Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2025 [IFRS] |
| 07/31/2024 15:30 |
Conference on Q1 FY2024 (April 1, 2024 to June 30, 2024) Financial Results |
| 07/31/2024 15:30 |
Sumitomo Pharma Announces Offering an Early Retirement Program to Employees in Japan for Business Structural Reform |
| 07/31/2024 15:30 |
Notice Concerning Finance Income |
| 07/31/2024 15:30 |
Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2025 |
| 07/01/2024 10:00 |
Corporate Governance Report |
| 05/14/2024 13:00 |
Sumitomo Pharma Appoints Toru Kimura as President and CEO and Changes in Board of Directors Including Representative Director and Executive Officer. |
| 05/14/2024 13:00 |
Sumitomo Pharma Announces Reduction in Executive Remuneration |
| 05/14/2024 13:00 |
Conference on FY2023 (April 1,2023 to March 31, 2024) Financial Results |
| 05/14/2024 13:00 |
Summary of Consolidated Financial Results for the Year Ended March 31, 2024 [IFRS] |
| 05/14/2024 13:00 |
Supplementary Financial Data (IFRS) for the Year Ended March 31, 2024 |
| 05/09/2024 19:30 |
Notice of Company Split of the Frontier Business and Notice of Business Acquisition by a Wholly-Owned Subsidiary of the Company |
| 04/30/2024 08:45 |
Conference on Financial Forecasts Revision for FY2023 and Financial Forecasts for FY2024 |
| 04/30/2024 08:30 |
Sumitomo Pharma Announces Its Financial Forecasts Revision for FY2023, Financial and Dividend Forecasts for FY2024 |
| 04/30/2024 08:30 |
Notice Concerning Impairment Losses, Business Structure Improvement Expenses, and Finance Income |
